Back to top
more

Metagenomi Therapeutics, Inc. (MGX)

(Delayed Data from NSDQ)

$1.39 USD

1.39
184,527

+0.03 (2.21%)

Updated Apr 8, 2026 04:00 PM ET

After-Market: $1.39 0.00 (0.00%) 7:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (96 out of 243)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -4.35% and -54.84%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Amphastar (AMPH) delivered earnings and revenue surprises of -24.49% and -5.63%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Metagenomi (MGX) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Metagenomi (MGX) delivered earnings and revenue surprises of +8.33% and -6.44%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of +4.17% and +242.30%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +19.68% and +10.35%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -7.69% and -4.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Metagenomi (MGX) is a Great Momentum Stock to Buy

by Zacks Equity Research

Does Metagenomi (MGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Metagenomi (MGX) delivered earnings and revenue surprises of +20.59% and +20.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Theravance Bio (TBPH) delivered earnings and revenue surprises of +42.86% and +53.76%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Xeris Biopharma (XERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Xeris Biopharma (XERS) delivered earnings and revenue surprises of +66.67% and +10.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?